Clinical outcomes of patients with primary refractory metastatic renal cell carcinoma receiving second-line (2L) therapies: An International Metastatic Database Consortium (IMDC) study.
Marc Eid(Harvard University), Daniel Yick Chin Heng(University of Calgary), Jeffrey Graham(University of Calgary), David Maj(University of Calgary), Razane El Hajj Chehade(Dana-Farber Cancer Institute), J. Connor Wells(Queen's University), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Ravindran Kanesvaran(University of Ioannina), Toni K. Choueiri(Harvard University), Liliana Ascione(Harvard University), Rana R. McKay(University of California San Diego), Wanling Xie(Dana-Farber Cancer Institute), Lori Wood(Dalhousie University), Cristina Suárez(Complejo Hospitalario de Salamanca), Thomas Powles(Queen Mary University of London), Neeraj Agarwal(University of Utah), Guillermo de Velasco(Dana-Farber Cancer Institute), Karl Semaan(Broad Institute), Martín Zarbá(University of Calgary)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k